| Literature DB >> 35142858 |
Lianju Qin1, Jing Zhang2, Yujie Xiao2, Kang Liu2, Yugui Cui1, Fangyan Xu2, Wenkai Ren2, Yanggang Yuan2, Chunyan Jiang1, Song Ning1, Xiaoxue Ye2, Ming Zeng2, Hanyang Qian2, Anning Bian2, Fan Li2, Guang Yang2, Shaowen Tang3, Zhihong Zhang4, Juncheng Dai3, Jing Guo5, Qiang Wang6, Bin Sun2, Yifei Ge2, Chun Ouyang2, Xueqiang Xu2, Jing Wang2, Yaoyu Huang2, Hongqing Cui2, Jing Zhou1, Meilian Wang7, Zhonglan Su8, Yan Lu8, Di Wu8, Jingping Shi9, Wei Liu10, Li Dong11, Yinbing Pan12, Baiqiao Zhao2,13, Ying Cui2,14, Xueyan Gao2,15, Zhanhui Gao2,16, Xiang Ma1, Aiqin Chen1, Jie Wang1, Meng Cao1, Qian Cui1, Li Chen1, Feng Chen17, Youjia Yu17, Qiang Ji17, Zhiwei Zhang17, Mufeng Gu18, Xiaojun Zhuang18, Xiaolin Lv2, Hui Wang2, Yanyan Pan2, Ling Wang2, Xianrong Xu2, Jing Zhao19, Xiuqin Wang20, Cuiping Liu21, Ningxia Liang22, Changying Xing2, Jiayin Liu1, Ningning Wang2.
Abstract
Calciphylaxis is a rare disease characterized histologically by microvessel calcification and microthrombosis, with high mortality and no proven therapy. Here, we reported a severe uremic calciphylaxis patient with progressive skin ischemia, large areas of painful malodorous ulcers, and mummified legs. Because of the worsening symptoms and signs refractory to conventional therapies, treatment with human amnion-derived mesenchymal stem cells (hAMSCs) was approved. Preclinical release inspections of hAMSCs, efficacy, and safety assessment, including cytokine secretory ability, immunocompetence, tumorigenicity, and genetics analysis in vitro, were introduced. We further performed acute and long-term hAMSC toxicity evaluations in C57BL/6 mice and rats, abnormal immune response tests in C57BL/6 mice, and tumorigenicity tests in neonatal Balbc-nu nude mice. After the preclinical research, the patient was treated with hAMSCs by intravenous and local intramuscular injection and external supernatant application to the ulcers. When followed up to 15 months, the blood-based markers of bone and mineral metabolism improved, with skin soft tissue regeneration and a more favorable profile of peripheral blood mononuclear cells. Skin biopsy after 1-month treatment showed vascular regeneration with mature noncalcified vessels within the dermis, and 20 months later, the re-epithelialization restored the integrity of the damaged site. No infusion or local treatment-related adverse events occurred. Thus, this novel long-term intravenous combined with local treatment with hAMSCs warrants further investigation as a potential regenerative treatment for uremic calciphylaxis due to effects of inhibiting vascular calcification, stimulating angiogenesis and myogenesis, anti-inflammatory and immune modulation, multidifferentiation, re-epithelialization, and restoration of integrity.Entities:
Keywords: calciphylaxis; chronic kidney disease; human amnion-derived mesenchymal stem cells; multidisciplinary rescue; preclinical research; regenerative medicine; vascular calcification
Mesh:
Year: 2022 PMID: 35142858 PMCID: PMC9205756 DOI: 10.1093/jmcb/mjac010
Source DB: PubMed Journal: J Mol Cell Biol ISSN: 1759-4685 Impact factor: 8.185